Abbonarsi

ILC2 activation by keratinocyte-derived IL-25 drives IL-13 production at sites of allergic skin inflammation - 08/06/20

Doi : 10.1016/j.jaci.2020.02.026 
Juan Manuel Leyva-Castillo, PhD a, , Claire Galand, PhD a, , Shunya Mashiko, PhD b, Robert Bissonnette, MD c, Alex McGurk, BA a, Steven F. Ziegler, PhD d, e, Chen Dong, PhD f, g, Andrew N.J. McKenzie, PhD h, Marika Sarfati, MD, PhD b, Raif S. Geha, MD a,
a Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, Mass 
b Immunoregulation Laboratory, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, Canada 
c Innovaderm Research, Montreal, Québec, Canada 
d Immunology Program, Benaroya Research Institute, Seattle, Wash 
e Department of Immunology, University of Washington School of Medicine, Seattle, Wash 
f Institute for Immunology and School of Medicine, Tsinghua University, Beijing, China 
g Beijing Key Lab for Immunological Research on Chronic Diseases, Beijing, China 
h Medical Research Council, Laboratory of Molecular Biology, Cambridge, United Kingdom 

Corresponding author: Juan-Manuel Leyva-Castillo, PhD, Boston Children's Hospital, Division of Immunology, One Blackfan Circle, Boston, MA 02115.Boston Children's HospitalDivision of ImmunologyOne Blackfan CircleBostonMA02115∗∗Raif S. Geha, MD, Boston Children's Hospital, Division of Immunology, One Blackfan Circle, Boston, MA 02115.Boston Children's HospitalDivision of ImmunologyOne Blackfan CircleBostonMA02115

Abstract

Background

Atopic dermatitis skin lesions demonstrate increased expression of IL-25 by keratinocytes and increased numbers of type 2 innate lymphoid cells (ILC2s) that express high levels of IL-25 receptor (IL-25R). IL-13 is expressed in atopic dermatitis skin lesions and plays an important role in pathogenesis of the disease.

Objective

Our aim was to determine the role of IL-25 and ILC2s in a mouse model of antigen-driven allergic skin inflammation.

Methods

Wild-type mice; mice that express an Il13-driven enhanced green fluorescent protein; and mice that lack IL-25R, IL-25 in keratinocytes, or IL-13 or IL-25R in ILC2s were subjected to acute or chronic epicutaneous sensitization with ovalbumin. Sensitized skin was examined by histology for epidermal thickening. Cellular infiltrates were analyzed for surface markers and intracellular expression of enhanced green fluorescent protein by flow cytometry. Gene expression was quantitated by RT quantitative PCR.

Result

In both acute and chronic antigen-driven allergic skin inflammation, signaling by keratinocyte-derived IL-25 in ILC2s is important for epidermal hyperplasia, dermal infiltration by CD4+ T cells, and cutaneous expression of Il13 and the IL-13–dependent TH2-cell–attracting chemokines Cc17 and Ccl22. ILCs are the major source of IL-13 in acutely sensitized mouse skin, whereas T cells are its major source in chronically sensitized mouse skin.

Conclusion

ILC2 activation by IL-25 is essential for IL-13 expression at sites of allergic skin inflammation.

Il testo completo di questo articolo è disponibile in PDF.

Graphical abstract




Il testo completo di questo articolo è disponibile in PDF.

Key words : Atopic dermatitis, IL-25, IL-13, ILC2

Abbreviations used : AD, eGFP, IL-25R, ILC, ILC2, MC, TEWL, TSLP, WT


Mappa


 Funded by the National Institutes of Health/National Institute of Allergy and Infectious Diseases Atopic Dermatitis Research Network (grant U19AI117673); the National Institutes of Health (grant AI113294-01A1); and the National Institute of Allergy and Infectious Diseases (T32 training grant 5T32AI007512-32).
 Disclosure of potential conflict of interest: J. M. Leyva-Castillo was supported by a postdoctoral fellowship from Consejo Nacional de Ciencia y Tecnología (Mexico) and a Boston Children’s Hospital Office of Faculty Development/Basic/Translational Research Executive Committee (BTREC) and the Clinical and Translational Research Executive Committee (CTREC) Faculty Career Development Fellowship. The rest of the authors declare that they have no relevant conflicts of interest.


© 2020  MRC Laboratory of Molecular Biology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 145 - N° 6

P. 1606 - Giugno 2020 Ritorno al numero
Articolo precedente Articolo precedente
  • Clinical factors associated with acute exacerbations of chronic rhinosinusitis
  • Jason H. Kwah, Shaan N. Somani, Whitney W. Stevens, Robert C. Kern, Stephanie S. Smith, Kevin C. Welch, David B. Conley, Bruce K. Tan, Leslie C. Grammer, Amy Yang, Robert P. Schleimer, Anju T. Peters
| Articolo seguente Articolo seguente
  • Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis
  • Helen He, Hemant Suryawanshi, Pavel Morozov, Jesús Gay-Mimbrera, Ester Del Duca, Hyun Je Kim, Naoya Kameyama, Yeriel Estrada, Evan Der, James G. Krueger, Juan Ruano, Thomas Tuschl, Emma Guttman-Yassky

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.